Bovie Medical Corporation Announces FDA Clearance to Market GI Generator.MELVILLE, N.Y. -- Bovie Medical Corporation (the "Company") (Amex: BVX BVX Bulk Viscosity of Xenon ), a manufacturer and marketer of electrosurgical products, today announced that it has received U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) 510(k) clearance to market the ICON GI(TM) for gastroenterological procedures. The GI device has been designed in conjunction with input from GI physicians and nurses, offering many features including digital output, a touch screen interface, physician preference database, neutral electrode electrode, terminal through which electric current passes between metallic and nonmetallic parts of an electric circuit. In most familiar circuits current is carried by metallic conductors, but in some circuits the current passes for some distance through a monitoring, and common sense messages. Andrew Makrides, president of Bovie stated "We continue to make progress designing and developing proprietary innovative electrosurgical devices for the medical community. The ICON GI(TM) accelerates our shift from being highly dependent on OEM (Original Equipment Manufacturer) The rebranding of equipment and selling it. The term initially referred to the company that made the products (the "original" manufacturer), but eventually became widely used to refer to the organization that buys the products and contracts toward the marketing and sale of our own brand of products. We look forward to the introduction of the device at the American College American College is the name of:
Mr. Makrides added, "The Company is establishing specialty distribution channels both domestically and internationally as well as entering into discussions with potential strategic marketing and distribution partners." This document may contain some forward looking statements, particularly regarding operational prospects in 2006 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company's SEC filings. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion